Related Experiment Video

Updated: Jul 8, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Sudden cardiac death risk factors in patients with heart failure treated with carvedilol

Jadwiga Nessler1, Bohdan Nessler, Mariusz Kitliński

  • 1Klinika Choroby Wieńcowej, Instytut Kardiologii, Collegium Medicum UJ, Kraków. jnessler@interia.pl

Kardiologia Polska
|January 9, 2008
PubMed

Insights

Prolonged carvedilol therapy significantly reduced sudden cardiac death risk factors in chronic heart failure patients. This beta-blocker improved heart function and heart rate variability, lowering overall risk.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) patients, particularly those in NYHA class II and III, face a high risk of sudden cardiac death (SCD).
  • Identifying and mitigating SCD risk factors is crucial for managing CHF patients.

Purpose of the Study:

  • To assess the impact of extended carvedilol treatment on reducing SCD risk in individuals with CHF.
  • To evaluate changes in specific SCD risk markers after one year of carvedilol therapy.

Main Methods:

  • 86 CHF patients (NYHA class II-III) not on beta-blockers received carvedilol for 12 months.
  • Risk factors for SCD, including left ventricular ejection fraction (LVEF), heart rate variability (HRV), and ECG parameters, were analyzed at baseline and after treatment.
  • Angiography, echocardiography, resting ECG, 24-hour ECG, and signal-averaged ECG were utilized.

Main Results:

  • Carvedilol therapy significantly reduced the prevalence of high resting heart rate (HRs >75/min), low LVEF (<30%), and blunted HRV (SDNN <100 ms).
  • The overall number of SCD risk factors per patient decreased significantly after one year.
  • Patients who died suddenly had a higher burden of SCD risk factors at baseline compared to survivors.

Conclusions:

  • Prolonged beta-adrenergic blockade with carvedilol effectively lowers SCD risk in CHF patients.
  • Improvements in LVEF, resting heart rate, and HRV are key mechanisms by which carvedilol reduces SCD risk.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...